Danskstiftet selskab vil spinde guld på 40 år gammelt Leo-middel i USA

Siden opkøbet af et gammelt Leo Pharma-antibiotikum har danskstiftede Utility Therapeutics stormet gennem den regulatoriske proces i USA, hvor man vil introducere midlet. Nu skal selskabet på kapitaljagt til at finansiere de kliniske programmer.
Photo: Renata Horvat / Stock.xchng
Photo: Renata Horvat / Stock.xchng

Mark Beards har knap nok været direktør i britiske Utility Therapeutics i et år, men tingene er gået stærkt, siden han satte sig i direktørstolen ved årsskiftet.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading